Abstract:Introduction Cirrhosis is a condition in which the liver becomes fibrotic following damage to the liver and transforms the architecture of the organ into regenerative nodules. The disease is caused 30% by HCV infection, resulting in a risk of severe complications and death. Since the use of direct-acting antivirals ( DAAs) for the treatment of chronic HCV, sustained virological response (SVR) rates have begun to increase, even in treatment-resistant cases. Studies have also shown that DAAs may have applications in other viral diseases and even In the treatment of breast cancer. Aim of the study The purpouse of our study was to review scientific articles to show the efficiency and potential use of DAAs in the treatment of chronic HCV, and to identify possible directions for further research. Methods and materials We reviewed the English literature in the PubMed, using the key words: "simeprevir" ; "sofosbuvir" ; "velpatasvir" ; "telaprevir" ; "chronic hepatitis C". Results Studies have shown that the therapeutic regimens currently being designed with (DAAs) offer the possibility of treating almost the entire population with hepatitis C, while reducing side effects of interferon therapy such as increased AST, ALT activities, diarrhoea, vomiting, nausea and depression. They remain effective and tolerable, regardless of the stage of cirrhosis and associated serious co-morbidities. Analysis of studiem shows, that DAAs also show efficacy against other disease such as breast cancer, MRSA infections, SARS-CoV-2 or flavivirus infection. Conclusion All (DAAs) are effective in the treatment of patients with HCV, including cirrhosis. They result in significant improvements in prognosis and clinical outcomes. Promising results have been obtained in published data on the effect of DAAs against disease entities other than HCV, suggesting the rationale for future clinical trials to further the hypothesis of the increased potential of these drugs.

Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals

Clinical efficacy and safety of ravidavir-based antiretroviral regimen in treatment of patients with chronic hepatitis C

Mechanism of resistance to direct-acting antivirals in hepatitis C treatment and management

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.

Recent progress in direct-acting antiviral agents for chronic hepatitis C

Recent Progress and Future Prospects of Direct-Acting Antiviral Agents for Chronic Hepatitis C

Personalized care approaches to hepatitis C therapy: recent advances and future directions

Cost effectiveness of hepatitis C direct acting agents

Safety of direct antiviral agents for treatment of hepatitis C virus infection

Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

[Selection of Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection].

Recent Advance in Antiviral Drugs for Hepatitis C.

Clinical practice of direct-acting antiviral agents for chronic HCV infection

Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies

A Synopsis of Hepatitis C Virus Treatments and Future Perspectives

The Real-World Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C in Patients Active Malignancies

Key tasks in the era of direct-acting antiviral for hepatitis C in China

Barriers to Treatment of Hepatitis C Virus in the Direct-Acting Antiviral Era

From non-A, non-B hepatitis to hepatitis C virus cure

Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease